These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26832957)

  • 21. Clinical course of sly syndrome (mucopolysaccharidosis type VII).
    Montaño AM; Lock-Hock N; Steiner RD; Graham BH; Szlago M; Greenstein R; Pineda M; Gonzalez-Meneses A; Çoker M; Bartholomew D; Sands MS; Wang R; Giugliani R; Macaya A; Pastores G; Ketko AK; Ezgü F; Tanaka A; Arash L; Beck M; Falk RE; Bhattacharya K; Franco J; White KK; Mitchell GA; Cimbalistiene L; Holtz M; Sly WS
    J Med Genet; 2016 Jun; 53(6):403-18. PubMed ID: 26908836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synchrotron X-ray diffraction and scanning electron microscopy to understand enamel affected by metabolic disorder mucopolysaccharidosis.
    Khan MA; Addison O; James A; Hendriksz CJ; Al-Jawad M
    Micron; 2016 Apr; 83():48-53. PubMed ID: 26896739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.
    Polgreen LE; Vehe RK; Rudser K; Kunin-Batson A; Utz JJ; Dickson P; Shapiro E; Whitley CB
    Mol Genet Metab; 2016 Apr; 117(4):427-30. PubMed ID: 26873528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural history of growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS).
    Parini R; Jones SA; Harmatz PR; Giugliani R; Mendelsohn NJ
    Mol Genet Metab; 2016 Apr; 117(4):438-46. PubMed ID: 26846156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.
    Taylor M; Khan S; Stapleton M; Wang J; Chen J; Wynn R; Yabe H; Chinen Y; Boelens JJ; Mason RW; Kubaski F; Horovitz DDG; Barth AL; Serafini M; Bernardo ME; Kobayashi H; Orii KE; Suzuki Y; Orii T; Tomatsu S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):e226-e246. PubMed ID: 30772512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.
    Péntek M; Gulácsi L; Brodszky V; Baji P; Boncz I; Pogány G; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Taruscio D; Iskrov G; Schieppati A; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():89-98. PubMed ID: 27062257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison.
    Eisengart JB; Rudser KD; Xue Y; Orchard P; Miller W; Lund T; Van der Ploeg A; Mercer J; Jones S; Mengel KE; Gökce S; Guffon N; Giugliani R; de Souza CFM; Shapiro EG; Whitley CB
    Genet Med; 2018 Nov; 20(11):1423-1429. PubMed ID: 29517765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
    Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
    Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology of mucopolysaccharidoses.
    Khan SA; Peracha H; Ballhausen D; Wiesbauer A; Rohrbach M; Gautschi M; Mason RW; Giugliani R; Suzuki Y; Orii KE; Orii T; Tomatsu S
    Mol Genet Metab; 2017 Jul; 121(3):227-240. PubMed ID: 28595941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
    Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
    Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review.
    Conte F; Sam JE; Lefeber DJ; Passier R
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MPSI Manifestations and Treatment Outcome: Skeletal Focus.
    De Ponti G; Donsante S; Frigeni M; Pievani A; Corsi A; Bernardo ME; Riminucci M; Serafini M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I.
    Zhang T; Duong P; Dayuha R; Collins CJ; Beckman E; Thies J; Chang I; Lam C; Sun A; Scott AI; Thompson J; Singh A; Khaledi H; Gelb MH; Hahn SH
    Mol Genet Metab; 2022 Aug; 136(4):296-305. PubMed ID: 35787971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease.
    Liang Q; Vlaar EC; Catalano F; Pijnenburg JM; Stok M; van Helsdingen Y; Vulto AG; Unger WWJ; van der Ploeg AT; Pijnappel WWMP; van Til NP
    Mol Ther Methods Clin Dev; 2022 Jun; 25():520-532. PubMed ID: 35662813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of laminoplasty for patients with lysosomal storage disease including mucopolysaccharidosis and mucolipidoses: a retrospective cohort study.
    Terai H; Tamai K; Hoshino M; Toyoda H; Suzuki A; Takahashi S; Hori Y; Yabu A; Nakamura H
    Orphanet J Rare Dis; 2021 Sep; 16(1):401. PubMed ID: 34583711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I.
    Grant N; Taylor JM; Plummer Z; Myers K; Burrow T; Luchtman-Jones L; Byars A; Hammill A; Wusick K; Smith E; Leach J; Vadivelu S
    Front Pediatr; 2021; 9():606905. PubMed ID: 34178879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
    Köse S; Aerts-Kaya F; Uçkan Çetinkaya D; Korkusuz P
    Adv Exp Med Biol; 2021; 1347():135-162. PubMed ID: 33977438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.
    Hampe CS; Wesley J; Lund TC; Orchard PJ; Polgreen LE; Eisengart JB; McLoon LK; Cureoglu S; Schachern P; McIvor RS
    Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33572941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT).
    Guffon N; Pettazzoni M; Pangaud N; Garin C; Lina-Granade G; Plault C; Mottolese C; Froissart R; Fouilhoux A
    Orphanet J Rare Dis; 2021 Jan; 16(1):60. PubMed ID: 33517895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I.
    Giugliani R; Muschol N; Keenan HA; Dant M; Muenzer J
    Arch Dis Child; 2021 Jul; 106(7):674-679. PubMed ID: 33139350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.